Non-specific activity of (+/-)CP-96,345 in models of pain and inflammation.
Nagahisa
A
A
Department of Medicinal Biology, Pfizer Inc., Aichi, Japan.
Asai
R
R
Kanai
Y
Y
Murase
A
A
Tsuchiya-Nakagaki
M
M
Nakagaki
T
T
Shieh
T C
TC
Taniguchi
K
K
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002351:Carrageenan; D004305:Dose-Response Relationship, Drug; D004487:Edema; D006930:Hyperalgesia / Q000188:drug therapy; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology*; D064729:Neurokinin-1 Receptor Antagonists; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology*; D051381:Rats; D013237:Stereoisomerism; D013373:Substance P / Q000037:antagonists & inhibitors; D013997:Time Factors; D014700:Verapamil / Q000494:pharmacology
D001713:Biphenyl Compounds; D006993:Hypnotics and Sedatives; D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P; D002351:Carrageenan; D014700:Verapamil; C066892:CP 96345